๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Peking Union Medical College Hospital276 Beijing Tiantan Hospital214 Cancer Institute and Hospital, Chinese Academy of Medical Sciences197 AstraZeneca183 Peking University People's Hospital158
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Beijing

5484 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Study of Post-anesthesia Management in Patients Undergoing Neurosurgery
NCT04362709Anesthesia, Neurosurgery, Complication
Beijing Tiantan Hospital
Observational
10,000
Beijing
2019-12-02
Not yet open
Registry Study on Drug Therapy and Clinical Outcomes in Patients With Acute Coronary Syndrome
NCT04184583Drug Therapy, Acute Coronary Syndrome
Beijing Anzhen Hospital
Observational
10,000
Beijing
2019-12
Recruiting
MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)
NCT04110301Follicular Lymphoma and Marginal Zone Lymphoma
Beijing Mabworks Biotech Co., Ltd.
Phase 1/2
53
Beijing
2019-11-28
Active, closed
A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies
NCT03888105B-cell Non-Hodgkin Lymphoma (B-NHL)
Regeneron Pharmaceuticals
Phase 2
515
Beijing, Tianjin, Chongqing, Guangzhou, Harbin, Zhengzhou, Wuhan, Suzhou
2019-11-13
Active, closed
The PREDICT Study: Prospective Early Detection In a Population at High-risk for Common Malignant Tumor
NCT04405557Early Detection of Cancer
Geneplus-Beijing Co. Ltd.
Observational
757
Beijing, Shenzhen, Zhengzhou, Changsha, Nanjing, Changchun, Jinzhou, Chengdu
2019-11-12
Recruiting
CtDNA After Chemotherapy in Elderly Patients With Acute Leukemia
NCT04157569Acute Leukemia
Navy General Hospital, Beijing
Observational
200
Beijing
2019-11-05
Active, closed
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
NCT04025879Carcinoma, Non-Small-Cell Lung
Bristol-Myers Squibb
Phase 3
461
Beijing, Fuzhou, Hubei Sheng, Changsha, Shanghai, Chengdu, Hangzhou
2019-11-05
Recruiting
Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers
NCT06255197Lung Cancer, Lung Adenocarcinoma, Lung Squamous Cell Carcinoma, Non Small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
60,000
Beijing
2019-11-04
Recruiting
The Effect of PAP on ISSHL Comorbided With OSA
NCT04192656Sudden Hearing Loss, Obstructive Sleep Apnea
Beijing Tsinghua Chang Gung Hospital
Phase 4
102
Beijing
2019-11-01
Recruiting
China Research for Severe Spontaneous Intracerebral Hemorrhage๏ผˆCRISIH๏ผ‰
NCT05975398Severe Spontaneous Intracranial Hemorrhage, Long-term Antiplatelet Treatment, Emergency Surgery, Complications
Beijing Tiantan Hospital
Observational
2,000
Beijing
2019-11-01
Recruiting
Natural History and Clinical Features of Amyotrophic Lateral Sclerosis (ALS)
NCT04454892Amyotrophic Lateral Sclerosis
Peking University Third Hospital
Observational
3,000
Beijing
2019-11-01
Active, closed
Efficacy and Safety of Butylphthalide Soft Capsule for the Treatment of Vascular Dementia
NCT03804229Vascular Dementia
Capital Medical University
Phase 3
707
Beijing
2019-10-29
Recruiting
A Clinical Trial of TQB3455 Tablets in Patients With Hematological Malignancies
NCT06550713Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1
100
Beijing, Shijiazhuang, Harbin, Shanghai, Chengdu, Tianjin
2019-10-22
Recruiting
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
NCT03955445C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis
Novartis Pharmaceuticals
Phase 3
225
Beijing, Shanghai
2019-10-03
Recruiting
Chemoradiotherapy in Unresectable Esophageal Cancer
NCT04278287Esophageal Cancer, Chemoradiotherapy, Albumin-bound Paxlitaxel, Unresectable Malignant Neoplasm
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1/2
105
Anyang, Changsha, Nanjing, Beijing
2019-10-01
Active, closed
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT04033445Ulcerative Colitis
Janssen Research & Development, LLC
Phase 2/3
1,064
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Ganzhou, Guangzhou
2019-09-26
By invitation
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
NCT03683186PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension
United Therapeutics
Phase 3
1,000
Beijing, Guangzhou, Changsha, Shanghai
2019-09-23
Active, closed
Evaluation of the Efficacy and Safety of the Application of BeGraft Peripheral Stent Graft System
NCT04023370Iliac Artery Stenosis
Bentley InnoMed GmbH
Not applicable
182
Beijing, Shanghai, Suzhou, Tianjin, Wuhan, Zhejiang
2019-09-19
Active, closed
Perioperative Epidural Block and Dexamethasone in Pancreatic Cancer Surgery
NCT04025840Pancreatic Cancer, Surgery, Epidural Block, Dexamethasone
Peking University First Hospital
Phase 4
260
Beijing
2019-09-11
Active, closed
An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
NCT04076059Metastatic Hormone Sensitive Prostate Cancer
Astellas (Beijing) Pharmaceutical R&D Co., Ltd.
Phase 3
180
Beijing, Changchun, Changsha, Fuzhou, Guangzhou, Hangzhou, Nanchang, Shanghai
2019-09-11
Recruiting
Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma
NCT04047953Gastric Adenocarcinoma
Peking University Cancer Hospital & Institute
Not applicable
95
Beijing
2019-09-10
Recruiting
Low INR to Minimize Bleeding With Mechanical Valves Trial
NCT03636295Bleeding Post-mechanical Valve Replacement, Thromboembolism Post-mechanical Valve Replacement
Population Health Research Institute
Phase 3
2,625
Beijing
2019-09-05
Active, closed
A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer
NCT04077463Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC
Phase 1
701
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan
2019-09-04
Recruiting
Quantitative Susceptibility Biomarker and Brain Structural Property for Cerebral Cavernous Malformation Related Epilepsy
NCT04076449Cavernous Malformation, Cerebral, Cavernous Angioma, Cavernous Hemangioma, Cavernous Hemangioma of Brain
yuanli Zhao
Observational
200
Beijing
2019-09-03
Recruiting
Adjuvant Chemotherapy for High Malignant Prostate Cancer
NCT06864533Prostate Cancer, Radiation Therapy, Chemotherapy, Gleason Score
Peking University First Hospital
Observational
315
Beijing, Shenzhen, Baoding
2019-09-01
Active, closed
A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
NCT04002297Mantle Cell Lymphoma; Non-Hodgkin Lymphoma
BeOne Medicines
Phase 3
510
Beijing, Fuzhou, Quanzhou, Guangzhou, Harbin, Zhengzhou, Wuhan, Changsha
2019-08-20
Active, closed
Observational Evaluation of Atopic Dermatitis in Pediatric Patients
NCT03687359Dermatitis Atopic
Sanofi
Observational
1,860
Beijing, Changsha, Chongqing, Guangzhou, Harbin, Shanghai, Shenzhen, Suzhou
2019-08-15
Recruiting
The Safety/Efficacy Study of Human Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLifeยฎ-LDP) for Lumbar Discogenic Pain
NCT04104412Lumbar Discogenic Pain
Sclnow Biotechnology Co., Ltd.
Phase 1
242
Beijing
2019-08-15
Active, closed
Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia
NCT04119050Warm Autoimmune Hemolytic Anemia
Janssen Research & Development, LLC
Phase 2/3
118
Beijing, Changchun, Chengdu, Guangzhou, Haikou, Hangzhou, Lanzhou, Nanjing
2019-08-15
Active, closed
A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
NCT04077723Lymphoma, Non-Hodgkin
Hoffmann-La Roche
Phase 1/2
498
Beijing, Jinan, Shanghai, Xiamen
2019-08-13
Recruiting
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
NCT04064060Myelodysplastic Syndromes (MDS), Beta-thalassemia, Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis
Celgene
Phase 3
665
Beijing, Guangzhou, Shanghai, Chengdu, Tianjin, Hangzhou
2019-08-12
Recruiting
Pan Tumor Rollover Study
NCT03899155Cancer
Bristol-Myers Squibb
Phase 2
1,500
Hefei, Beijing, Guangzhou, Harbin, Changsha, Nanjing, Changchun, Xi'an
2019-08-09
Active, closed
ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC
NCT04143607Locally Advanced or Metastatic NSCLC
Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Phase 3
337
Beijing, Nanjing
2019-07-23
Recruiting
Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
NCT04270591C-Met Exon 14 Mutation
Haihe Biopharma Co., Ltd.
Phase 1/2
183
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Haikou, Harbin, Zhengzhou
2019-07-15
Active, closed
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
NCT04008797Endometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms
Eisai Inc.
Phase 1/2
301
Beijing, Changchun, Fuzhou, Guangzhou, Jinan, Kunming, Shanghai, Shenzhen
2019-07-11
Active, closed
Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)
NCT03974022Non-Small Cell Lung Cancer
Dizal Pharmaceuticals
Phase 1/2
315
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou
2019-07-09
Active, closed
Treatment Effects of Chinese Medicine (Yi-Qi-Qing-Jie Herbal Compound) Combined With Immunosuppression Therapies in IgA Nephropathy Patients With High-risk of ESRD
NCT03418779IgA Nephropathy at High Risk of Developing ESRD
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Phase 2/3
60
Beijing
2019-07-04
Active, closed
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)
NCT04035486Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
587
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Haikou, Hangzhou
2019-07-02
Recruiting
Comparing the Efficacy and Safety Between Continuous Subcutaneous Beinaglutide and CSII for Newly Diagnosed T2DM Patients
NCT03987308Type 2 Diabetic Patients, T2DM (Type 2 Diabetes Mellitus), T2DM
Beijing Hospital
Not applicable
115
Beijing, Guangzhou, Harbin, Nanjing, Xuzhou, Changchun, Xi'an, Luzhou
2019-07-02
Active, closed
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC
NCT03997123Triple Negative Breast Neoplasms
AstraZeneca
Phase 3
923
Beijing, Changchun, Changsha, Chengdu, Foshan, Guangzhou, Guiyang, Haikou
2019-06-25
Active, closed
Bronchial Ablation for Treatment of Asthma (BATA) Trial
NCT03765307Asthma
SyMap Medical (Suzhou), Ltd.
Not applicable
160
Beijing, Guangzhou, Shenzhen, Shijiazhuang, Qiqihar, Nanjing, Suzhou, Xuzhou
2019-06-18
Recruiting
Developing Effectiveness Evaluation and Therapeutic Programs of Rehabilitation
NCT03979235Healthy Volunteers, Motor Deficits, Dysphagia
National Research Center for Rehabilitation Technical Aids
Observational
40
Beijing
2019-06-05
Recruiting
Fall Prevention in Elderly: Mechanisms and Strategies
NCT03981471Elderly
National Research Center for Rehabilitation Technical Aids
Not applicable
4,000
Beijing
2019-06-03
Active, closed
Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer ๏ผˆFLAG๏ผ‰
NCT03787992Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer
Allist Pharmaceuticals, Inc.
Phase 3
358
Beijing
2019-05-30
Active, closed
Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma
NCT03967977Urothelial Carcinoma
BeiGene
Phase 3
420
Hefei, Beijing, Chongqing, Fuzhou, Quanzhou, Xiamen, Guangzhou, Harbin
2019-05-29
Active, closed
Genotyping GUided Antiplatelet theRapy in pAtieNts Treated With Drug Eluting stEnts (GUARANTEE)
NCT03783351Angina, Stable, Acute Coronary Syndrome, Drug-Eluting Stents, Genotype
Beijing Anzhen Hospital
Not applicable
4,009
Beijing
2019-05-27
Recruiting
APG-2449 in Patients With Advanced Solid Tumors
NCT03917043Advanced Solid Cancer, Non Small Cell Lung Cancer, Esophageal Cancer, Ovarian Cancer
Ascentage Pharma Group Inc.
Phase 1
165
Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Hangzhou
2019-05-27
Active, closed
A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)
NCT03930953Lymphoma, Non-Hodgkin
Celgene
Phase 1/2
438
Beijing, Guangzhou, Zhengzhou, Wuhan, Shenyang, Shanghai, Tianjin
2019-05-20
Active, closed
A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma
NCT03952078T-cell Lymphoma
Corvus Pharmaceuticals, Inc.
Phase 1
151
Beijing, Pudong, Henan
2019-05-03
Active, closed
Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
NCT03847428Hepatocellular Carcinoma
AstraZeneca
Phase 3
908
Beijing, Bengbu, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou
2019-04-29
Active, closed
Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)
NCT03875235Biliary Tract Neoplasms
AstraZeneca
Phase 3
810
Baoding, Beijing, Bengbu, Chongqing, Foshan, Guangzhou, Hangzhou, Harbin
2019-04-16
Recruiting
Aspirin 50 mg vs. 100 mg in Elderly Cardiovascular Disease Patients
NCT07542860Atherosclerotic Cardiovascular Disease (ASCVD), Secondary Prevention, Cardiovascular Diseases
Peking University First Hospital
Observational
5,448
Beijing
2019-04-10
Recruiting
A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
NCT03773965Juvenile Idiopathic Arthritis
Eli Lilly and Company
Phase 3
190
Beijing, Chongqing, Nanjing, Suzhou
2019-04-05
Recruiting
An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia
NCT03813407Hyperkalaemia
AstraZeneca
Phase 3
140
Beijing, Changsha, Chengdu, Chongqing, Hangzhou, Hefei, Shanghai
2019-04-02
Recruiting
OH2 Oncolytic Viral Therapy in Solid Tumors
NCT03866525Solid Tumor, Gastrointestinal Cancer
Binhui Biopharmaceutical Co., Ltd.
Phase 1/2
300
Beijing
2019-04-02
Active, closed
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
NCT03887455Early Alzheimer's Disease
Eisai Inc.
Phase 3
1,906
Beijing, Guangzhou, Shijiazhuang, Zhengzhou, Changsha, Baotou, Nanjing, Changchun
2019-03-27
Active, closed
A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer
NCT03816163Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
Astellas Pharma Global Development, Inc.
Phase 2
393
Beijing, Changchun, Chongqing, Guangdong, Guangzhou, Harbin, Hubei, Jiangsu
2019-03-15
Active, closed
Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
NCT03833154Carcinoma, Non-Small-Cell Lung
AstraZeneca
Phase 3
724
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Hangzhou, Hefei, Jinan
2019-03-06
Not yet open
Endoscopic Submucosal Dissection Versus Surgery in the Treatment of Early Gastric Cancer
NCT03857737Early Gastric Cancer
Peking University Third Hospital
Not applicable
300
Beijing
2019-03-01
Active, closed
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
NCT03836261Chronic Lymphocytic Leukemia
Acerta Pharma BV
Phase 3
984
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanchang
2019-02-25
Active, closed
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
NCT03748641Castration-Resistant Prostatic Cancer
Janssen Research & Development, LLC
Phase 3
765
Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanjing, Ningbo, Shanghai
2019-01-25
Recruiting
Coexistence of Cerebral and Coronary Atherosclerosis in Acute Ischemic Cerebrovascular Disease Patients Registry
NCT03788512Coexistence of Cerebral and Coronary Atherosclerosis, Acute Ischemic Cerebrovascular Disease
Xuanwu Hospital, Beijing
Observational
500
Beijing
2019-01-12
Active, closed
Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX
NCT03754790Hemophilia
Genzyme, a Sanofi Company
Phase 3
281
Beijing, Changsha, Chengdu, Guangzhou, Guiyang, Hangzhou, Jinan, Kunming
2019-01-09
Active, closed
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients
NCT03737643Advanced Ovarian Cancer
AstraZeneca
Phase 3
1,407
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Guangzhou
2019-01-04
Recruiting
Different Methods of Capecitabine in Patients With Non-PCR After Neoadjuvant Therapy for TNBC
NCT06700382Triple Negative Breast Cancer
Shu Wang
Observational
1,166
Beijing
2019-01-01
Recruiting
Development and Application of a Thrombosis Risk Prediction Model in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors
NCT06950697Lung Cancer, Venous Thromboembolism, Arterial Thromboembolism, Immune Checkpoint Inhibitors (ICIs)
Beijing Chao Yang Hospital
Observational
2,400
Zhengzhou, Hohhot, Beijing
2019-01-01
Recruiting
Adjuvant Therapy With Neratinib in HER2 Positive Early Breast Cancer
NCT06693024HER2-positive Breast Cancer
Shu Wang
Observational
2,806
Beijing
2019-01-01
Recruiting
Four Cycles Taxane With Trastuzumab and Pertuzumab Neoadjuvant Therapy Among Low Risk HER2 Positive Patients
NCT06722599HER2-positive Breast Cancer
Shu Wang
Observational
171
Beijing
2019-01-01
Recruiting
Clinical and Imaging Cohort of Neuroinflammation Diseases in China (CLUE)
NCT04106830NMO Spectrum Disorder, MRI, Multiple Sclerosis, MOGAD
Beijing Tiantan Hospital
Observational
1,000
Beijing
2019-01-01
Recruiting
SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC
NCT06889649Radiation Therapy, Targeted Therapy, Immunotherapy, Renal Cancer Metastatic
Peking University First Hospital
Phase 2
30
Beijing
2019-01-01
Recruiting
De-escalation of Neoadjuvant Chemotherapy Regimens With Immunotherapy Among TNBC
NCT06692725Triple Negative Breast Cancer
Peking University People's Hospital
Observational
380
Beijing
2019-01-01
Recruiting
Cerebral Venous Thrombosis Cohort Study in China Mainland
NCT03919305Cerebral Venous Sinus Thrombosis, Deep Cerebral Vein Thrombosis, Cortical Vein Thrombosis
Capital Medical University
Observational
3,000
Beijing
2019-01-01
Recruiting
Adjuvant Therapy for Intermediate Risk HER2 Positive, Lymph Node Negative Early Breast Cancer With Chemotherapy Combined Target Therapy
NCT06711068HER2-positive Breast Cancer
Shu Wang
Observational
8,077
Beijing
2019-01-01
Recruiting
Multimodality Imaging in the Screening, Diagnosis and Risk StratifictiON of HFpEF
NCT04603404Heart Failure, Diastolic
Chinese Academy of Medical Sciences, Fuwai Hospital
Observational
430
Beijing
2019-01-01
Recruiting
Short-term and Long-term Outcomes of Colorectal Cancer Treated With Natural Orifice Specimen Extraction Surgery : a National Registry-based Study
NCT06350370Colorectal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
8,000
Beijing
2019-01-01
Recruiting
Biomarker-based Alzheimer's Disease Cohort Study (BASIC)
NCT07109999Alzheimer Disease
Xuanwu Hospital, Beijing
Observational
2,835
Beijing
2019-01-01
Recruiting
Chemotherapy Combined With Targeted Therapy for High-risk HER2 Positive and Lymph Node Negative Early Breast Cancer
NCT06722612HER2-positive Breast Cancer
Shu Wang
Observational
2,916
Beijing
2019-01-01
Recruiting
Adjuvant Therapy Choice for Non-pCR HER2 Positive Early Breast Cancer After Neoadjuvant Therapy
NCT06693037HER2-positive Breast Cancer
Shu Wang
Observational
2,092
Beijing
2019-01-01
Active, closed
Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)
NCT03722420Chronic Myeloid Leukemia, Chronic Phase
Il-Yang Pharm. Co., Ltd.
Phase 3
238
Beijing
2018-12-28
Active, closed
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
NCT03725059Breast Cancer
Merck Sharp & Dohme LLC
Phase 3
1,240
Heifei, Shanghai, Beijing, Fuzhou Fujian, Guangzhou, Shijiazhuang, Harbin, Zhengzhou
2018-12-27
Active, closed
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
NCT03734029Breast Cancer
Daiichi Sankyo
Phase 3
557
Hefei, Beijing, Fuzhou, Guangzhou, Harbin, Wuhan, Nanjing, Changchun
2018-12-27
Active, closed
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
NCT03711032High-risk Non-muscle Invasive Bladder Cancer
Merck Sharp & Dohme LLC
Phase 3
1,397
Beijing, Chongqing, Xiamen, Guangzhou, Shenzhen, Harbin, Zhengzhou, Wuhan
2018-12-24
Active, closed
A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer
NCT03800134Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
825
Beijing, Changsha, Changzhou, Chengdu, Guangzhou, Guiyang, Hangzhou, Hefei
2018-12-06
Active, closed
Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC
NCT03562637Triple Negative Breast Cancer
OBI Pharma, Inc
Phase 3
575
Beijing, Guangzhou, Nanning, Harbin, Wuhan, Changsha, Nanjing, Changchun
2018-12-05
Recruiting
The Comparision of Minimally-invasive and Open Pancreaticoduodenectomy for Pancreatic Cancer
NCT03747588Pancreatic Carcinoma, Surgery
Peking Union Medical College Hospital
Not applicable
100
Beijing
2018-12-01
Active, closed
A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma
NCT03778957Hepatocellular Carcinoma
AstraZeneca
Phase 3
724
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2018-11-30
Active, closed
A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients
NCT03706690Carcinoma, Non-Small-Cell Lung
AstraZeneca
Phase 3
407
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou
2018-11-27
Recruiting
Safety and Efficacy Study of A Viscoelastic-free Method for Implantable Collamer Lens (ICL) Implantation
NCT03059043Myopia
Wenzhou Medical University
Not applicable
60
Guangzhou, Changsha, Wenzhou, Beijing, Shanghai
2018-11-16
Recruiting
Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients
NCT03731442Esophageal Cancer
Chinese Academy of Medical Sciences
Phase 3
300
Beijing
2018-11-01
Active, closed
A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
NCT03539744Multiple Myeloma
AbbVie
Phase 3
265
Beijing, Guangzhou, Zhengzhou, Wuhan, Nanjing, Suzhou, Nanchang, Shenyang
2018-10-22
Active, closed
Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer
NCT03539536Non-small Cell Lung Cancer
AbbVie
Phase 2
270
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Baoding, Harbin, Zhengzhou
2018-10-10
Active, closed
A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).
NCT06105619Glioblastoma
Beijing Pearl Biotechnology Limited Liability Company
Phase 2/3
84
Beijing
2018-10-08
Active, closed
Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer
NCT03682068Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer
AstraZeneca
Phase 3
1,246
Beijing, Changchun, Changsha, Chongqing, Dalian, Guangzhou, Hangzhou, Jinan
2018-09-27
Active, closed
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
NCT03703297Small Cell Lung Cancer
AstraZeneca
Phase 3
730
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou
2018-09-27
Recruiting
Anti-platelet Effect of Berberine in Patients After Percutaneous Coronary Intervention
NCT03378934Coronary Artery Disease, Percutaneous Coronary Intervention
Peking Union Medical College Hospital
Phase 4
64
Beijing
2018-09-26
Recruiting
Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
NCT03736889MSI-H/dMMR Solid Tumors
BeiGene
Phase 2
200
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Huizhou, Meizhou, Hechi
2018-09-19
Recruiting
The Diagnostic Cut-off Value of Core Biomarkers of Alzheimer's Disease
NCT05020106Alzheimer's Disease
Capital Medical University
Observational
3,200
Beijing
2018-09-01
Recruiting
Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT
NCT03793517Stem Cell Transplant Complications, Leukemia, Myeloid, Acute, Leukemia Relapse
Peking University People's Hospital
Phase 2/3
55
Beijing
2018-09-01
Active, closed
A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer
NCT03523442Prostatic Neoplasms
Janssen Research & Development, LLC
Phase 1
19
Beijing, Nanjing, Shanghai
2018-08-31
Active, closed
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis
NCT03398135Ulcerative Colitis (UC)
AbbVie
Phase 3
1,242
Hefei, Beijing, Guangzhou, Shijiazhuang, Wuhan, Changsha, Huaian, Nanjing
2018-08-28
Rows per page Showing 5201–5300 of 5484
Previous 51 52 53 54 55 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing?page=53

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 5,484 of those studies with a site in Beijing.

How many clinical trials are recruiting in Beijing?

3,341 of the 5,484 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 966 have not yet opened recruitment, 1,001 are active but closed to new participants, and 176 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.